Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation : Sub-Analysis in Japanese Population in RE-LY Trial
スポンサーリンク
概要
- 論文の詳細を見る
Background: RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) is an international multicenter study (18,113 patients from 967 centers in 44 countries) that demonstrated the ability of dabigatran to reduce the occurrence of both stroke and hemorrhage in patients who had atrial fibrillation (AF) with high risks of stroke compared with patients who received warfarin. From Japan, 326 patients were randomized in RE-LY. Methods and Results: RE-LY was designed to compare 2 fixed doses (110mg or 150mg, twice daily) of dabigatran, each administered in a blinded manner, with open-label use of warfarin. There were no major differences in patient demographic information among the overall study population and Japanese patients. However, in Japanese patients, the proportion of prior stroke was higher but prior myocardial infarction was lower than in the overall. The yearly rate for the primary endpoints (stroke and systemic embolism) was 1.38, 0.67 and 2.65%/year for 110mg and 150mg dabigatran twice daily and warfarin, respectively. These results were similar to the overall results (1.54, 1.11 and 1.71%/year for each group, respectively). For any bleeding, the relative risk of dabigatran at 110mg and 150mg twice daily over warfarin was 0.79 and 1.06, respectively, which was similar to the findings overall (dabigatran 110mg twice daily: 0.78; 150mg twice daily: 0.91). Conclusions: In RE-LY, the efficacy and safety profiles of dabigatran for Japanese AF patients at high risk of stroke were essentially the same as for the study population overall. (Circ J 2011; 75: 800 - 805)
- 2011-03-25
著者
-
HORI Masatsugu
Osaka Medical Center for Cancer and Cardiovascular Disease
-
Connolly Stuart
Population Health Research Institute Mcmaster University And Hamilton Health Sciences
-
EZEKOWITZ Michael
Lankenau Institute for Medical Research and the Heart Center
-
REILLY Paul
Boehringer Ingelheim Pharmaceuticals Inc
-
YUSUF Salim
Population Health Research Institute, McMaster University and Hamilton Health Sciences
-
WALLENTIN Lars
Uppsala Clinical Research Center
-
Yusuf Salim
Population Health Research Institute Mcmaster University And Hamilton Health Sciences
-
Yusuf Salim
Population Health Research Institute And Mcmaster University
関連論文
- Effect of intracoronary thrombectomy on 30-day mortality in non-diabetic patients with acute hyperglycemia after acute myocardial infarction
- Impact of Diabetes Mellitus on Rehospitalization for Heart Failure Among Survivors of Acute Myocardial Infarction in the Percutaneous Coronary Intervention Era
- OE-294 A Functional Variation in a Gene Encoding One of Galectin-2 Binding Proteins Confers Risk of Myocardial Infarction in Asian Populations(OE50,Coronary Circulation/Chronic Coronary Disease (Basic/Clinical) (IHD),Oral Presentation (English),The 73rd A
- OE-009 Identification of a Locus on Chromosome 5p that Confers Risk of Coronary Artery Disease by Genome Wide Association Study(OE02,ACS/AMI (Basic) (IHD),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)
- FRS-071 Constitutive Autophagy Is Required to Maintain Cardiac Structure and Function in Aged Mouse Heart(FRS15,Novel Molecular Mechanisms of Heart Failure 1 (M),Featured Research Session (English),The 73rd Annual Scientific Meeting of The Japanese Circul
- FRS-061 Cardiac-specific Disruption of Calpain4 Revealed Its Cardioprotective Role in Response to Pressure Overload(FRS13,Novel Molecular Mechanisms of Heart Failure 2 (M),Featured Research Session (English),The 73rd Annual Scientific Meeting of The Japan
- 2 Total Management of Vulnerable Patients after Acute Myocardial Infarction(Comprehensive Risk Management for Prevention of Coronary Artery Disease,Symposium 16 (SY-16) (H),The 73rd Annual Scientific Meeting of The Japanese Circulation Society)
- 4 Primary PCI versus CABG in Patients with Acute Myocardial Infarction due to the Occlusion of the Left Main Coronary Artery(Therapeutic Decision Making for Coronary Artery Disease Among PCI, CABG, and Medication,Symposium 3 (SY-03) (IHD),The 73rd Annual
- 2 Biomarkers, Single Nucleotide Polymorphisms and Cardiovascular Risk after Acute Myocardial Infarction : Observations from the Osaka Acute Coronary Insufficiency Study (OACIS)(Biomarkers, Genetic Polymorphism, and Risk Estimation,Symposium 1 (SY-01) (H),
- PJ-054 Increased Cardiac Glucocorticoid Contribute to Promoting Cardiac Hypertrophy(Cardiac hypertrophy, basic/clinical(02)(M),Poster Session(Japanese),The 72nd Annual Scientific Meeting of the Japanese Circulation Society)